Journal of Medicinal Chemistry p. 493 - 503 (1989)
Update date:2022-07-30
Topics:
Bedford
Harris III
Howd
Goff
Koolpe
Petesch
Miller
Nolen III
Musallam
Pick
Jones
Koplovitz
Sultan
A series of structurally related mono- and bis-1,3-disubstituted 2-[(hydroxyimino)methyl]imidazolium halides were evaluated in vitro for their ability to reactivate electric eel, bovine, and human erythrocyte (RBC) acetylcholinesterases (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP) and 3,3-dimethyl-2-butyl methylphosphonofluoridate (soman, GD). All new compounds were characterized for (hydroxyimino)methyl acid dissociation constant, nucleophilicity, octanol-buffer partition coefficient, reversible AChE inhibition, and kinetics of reactivation of EPMP-inhibited AChEs. For GD-inhibited AChEs, maximal reactivation was used to compare compounds since rapid phosphonyl enzyme dealkylation 'aging' complicated interpretation of kinetic constants. For comparison, we also evaluated three known pyridinium therapeutics, 2-PAM, HI-6, and toxogonin. In vivo evaluation in mice revealed that when selected imidazolium compounds were coadministered with atropine sulfate, they were effective in providing lifesaving protection against both GD and EPMP challenges. This was a major accomplishment in the search for effective anticholinesterase therapeutics - the synthesis and preliminary evaluation of the first new monoquaternary soman antidotes with potencies superior to 2-PAM. Significantly, there was an apparent inverse relationship between in vitro and in vivo results; the most potent in vivo compounds proved to be the poorest in vitro reactivators. These results suggested that an alternative and possibly novel antidotal mechanism of protective action may be applicable for the imidazolium aldoxines. Selected compounds were also evaluated for their inhibition of AChE phosphonylation by GD and antimuscarinic and antinicotinic receptor blocking effects.
View MoreShanghai Taibao Pharmaceutical Technology Co., Ltd(expird)
Contact:021-52217366
Address:shanghai
Contact:0086-29-89196322
Address:North of the Fifth Keji Road, Hi-Tech Industrial Zone, Xi'an City, Shaanxi Province, China
Luoyang Aoda chemical Co.,Ltd.
Contact:+86-379-67518785 67516588
Address:MiaoWan industry district,YanShi City,Henan,China
Shanghai KFSL Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-39971718
Address:859 jiadingchengliu shanghai
Shenyang NovPharm Technology Co., Ltd.
Contact:.+86-24-24165786
Address:Room 306, Hongjin Mansion, No. 36-1, Wanliutang Rd., Shenhe District, Shenyang, Liaoning, P.R.C.
Doi:10.1055/s-1988-27522
(1988)Doi:10.1002/bkcs.11825
(2019)Doi:10.1246/bcsj.61.1669
(1988)Doi:10.1021/ja9049228
(2009)Doi:10.1016/S0040-4039(00)80407-4
(1988)Doi:10.1016/j.molcatb.2012.11.006
(2013)